ANIP
ANI Pharmaceuticals, Inc.
$77.61
-1.54
(-1.95%)
Mkt Cap
1.76B
Volume
195,166
52W Range
62.61-99.5
Sector
Healthcare
Beta
0.43
EPS (TTM)
4.11
P/E Ratio
18.88
Revenue (TTM)
923.71M
Rev Growth (5Y)
+33.5%
EPS Growth (5Y)
+29.6%
AlphaVal · Fair Value
What we estimate one share is worth
$203.34
Undervalued
strong signal
61.8% below fair value
Modeled from cash flows & growth.
AlphaQuality · Grade · Gated
How strong & durable the business is
F
Platform & Compounding FCF
30.0 / 100 pillar composite (overridden)
A platform business that compounds free cash flow — graded A–F vs. similar companies.
Company Description
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 883.37M | 614.38M | 486.82M | 316.38M | 216.14M | 208.47M | 206.55M | 201.58M | 176.84M | 128.62M | 76.32M | 55.97M |
| Net Income | 78.34M | (18.52M) | 18.78M | (47.90M) | (42.60M) | (22.55M) | 6.09M | 15.49M | (1.08M) | 3.93M | 15.38M | 28.75M |
| EPS | 3.50 | -1.04 | 0.95 | -3.05 | -3.40 | -1.88 | 0.51 | 1.33 | -0.09 | 0.34 | 1.34 | 2.61 |
| Free Cash Flow | 150.90M | 47.06M | 100.45M | (47.66M) | (20.32M) | (53.05M) | 18.08M | 56.16M | (68.57M) | (121.59M) | (15.42M) | (13.72M) |
| FCF / Share | 7.53 | 2.44 | 5.58 | -2.93 | -1.61 | -4.43 | 1.53 | 4.81 | -5.94 | -10.62 | -1.36 | -1.25 |
| Operating CF | 185.22M | 64.02M | 118.96M | (31.20M) | 3.32M | 15.27M | 45.63M | 67.07M | 39.42M | 27.47M | 17.26M | 22.03M |
| Total Assets | 1.44B | 1.28B | 904.42M | 760.09M | 771.60M | 461.19M | 456.79M | 430.60M | 412.14M | 322.86M | 285.26M | 263.71M |
| Total Debt | 325.19M | 624.09M | 285.67M | 286.52M | 287.37M | 185.69M | 185.75M | 183.01M | 201.51M | 120.64M | 113.43M | 110.69M |
| Cash & Equiv | 285.58M | 144.86M | 221.12M | 48.23M | 100.30M | 7.86M | 62.33M | 43.01M | 31.14M | 27.36M | 154.68M | 169.04M |
| Book Value | 540.72M | 428.53M | 457.60M | 338.54M | 358.74M | 195.70M | 212.79M | 197.26M | 174.76M | 169.65M | 160.08M | 139.78M |
| Return on Equity | 0.14 | -0.04 | 0.04 | -0.14 | -0.12 | -0.12 | 0.03 | 0.08 | -0.01 | 0.02 | 0.10 | 0.21 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 237.46M | 247.06M | 227.81M | 211.37M | 197.12M | 190.57M | 148.33M | 138.04M | 137.43M | 131.65M | 131.83M | 116.55M |
| Net Income | 29.49M | 27.49M | 24.13M | 8.55M | 15.68M | (10.28M) | (24.17M) | (2.29M) | 18.21M | 1.16M | 9.94M | 6.25M |
| EPS | 1.31 | 1.24 | 1.19 | 0.37 | 0.70 | -0.55 | -1.27 | -0.14 | 0.84 | 0.04 | 0.50 | 0.33 |
| Free Cash Flow | 47.05M | 6.51M | 37.89M | 68.90M | 15.14M | 13.38M | 7.66M | 12.96M | 13.69M | 39.96M | 27.62M | 13.80M |
| FCF / Share | 2.25 | 0.32 | 1.89 | 3.47 | 0.77 | 0.69 | 0.39 | 0.67 | 0.72 | 2.10 | 1.46 | 0.78 |
| Operating CF | 58.38M | 30.37M | 44.05M | 75.81M | 34.99M | 15.86M | 12.47M | 17.41M | 18.27M | 44.74M | 32.17M | 20.63M |
| Total Assets | 1.42B | 1.44B | 1.41B | 1.34B | 1.29B | 1.28B | 1.29B | 920.75M | 914.52M | 904.42M | 889.91M | 859.34M |
| Total Debt | 327.76M | 325.19M | 322.63M | 621.56M | 622.82M | 624.09M | 625.36M | 285.24M | 285.46M | 285.67M | 285.88M | 286.09M |
| Cash & Equiv | 311.18M | 285.58M | 262.61M | 217.80M | 149.80M | 144.86M | 144.98M | 240.11M | 228.60M | 221.12M | 193.08M | 161.71M |
| Book Value | 562.30M | 540.72M | 505.82M | 461.61M | 443.47M | 428.53M | 430.80M | 480.61M | 476.81M | 457.60M | 454.71M | 434.47M |
| Return on Equity | 0.05 | 0.05 | 0.05 | 0.02 | 0.04 | -0.02 | -0.06 | -0.00 | 0.04 | 0.00 | 0.02 | 0.01 |
ANIP News
Trump's generic drug tariffs: What they could mean for medicine prices, manufacturers and supply
Bessemer Group Inc. Acquires 19,800 Shares of ANI Pharmaceuticals, Inc. $ANIP
ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter
ANI Pharmaceuticals reports Phase 4 data for uveitis eye implant
ANI Pharmaceuticals reports Phase 4 data for uveitis eye implant
ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chronic Non-Infectious Uveitis
ANI Pharmaceuticals' CFO Sold $285,000 in Stock After a 32% Run
ANI Pharmaceuticals CFO Sells $240,000 in Stock After a 42% Cortrophin Surge
Here's Why ANI Pharmaceuticals (ANIP) is a Strong Growth Stock
ANI Pharmaceuticals: Rare Disease Growth At A Generics Multiple